Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Btg Plc LSE:BTG London Ordinary Share GB0001001592 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 833.50p 833.50p 834.00p 835.00p 833.50p 835.00p 243,213 16:35:13
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 620.5 -70.6 3.9 213.7 -

Btg Share Discussion Threads

Showing 5026 to 5045 of 6175 messages
Chat Pages: Latest  211  210  209  208  207  206  205  204  203  202  201  200  Older
DateSubjectAuthorDiscuss
17/11/2017
07:49
No doubt the lead up to Btg buying Ventura . Win win
bargainbob
16/11/2017
17:19
Invesco sold BTG to fund Vectura purchase?
dp1umb
16/11/2017
17:00
Some significant buying after the bell and the Invesco RNS.Any thoughts?
fhmktg
16/11/2017
16:55
The Voraxaze RNS is a good example of working with the key opinion formers to get credibility in an area of new usage - as seen with the copperhead study for Crofab.Could we hope to see a similar approach with Varithena please!
fhmktg
15/11/2017
17:44
The Crown Jewels were sold and the Samsung apple patents payment more than Louise, underpinned the share price.
bargainbob
15/11/2017
17:38
Gm,You are right - I had forgotten that LM joined as long ago as September 2004. However, before the effects of her management were recognised, the share price fell to as low as 78p in 2007, so that it can, I believe, be reasonably said that her influence has lifted the share price not seven but almost nine times.
retsig
15/11/2017
17:23
It crashed when FDA approval of varisolve happened on black Btg Friday . There was a rights issue at 80 p.
bargainbob
15/11/2017
15:23
Seven times ? what have I missed! This stock floated in the late 1990's as a spin off from two Government back Enterprise Companies and subsequently became owned by various venture capital Companies which wanted an exit hence the flotation. It was full of intellectual property, some pharmaceutical , some technology, acquired via UK Universities. BTG floated at maybe 97p or something similar( its so long ago!) and did little for many, many months with the venture capitalists becoming increasingly restive. Gradually institutions were introduced and a string of technology related news attracted increasing attention and amazingly the stock hit approx £20 a share in the 2000-1 tech boom. Trouble was the aftermath where the management had over promised with zeal. This upset institutional shareholders who pushed for change. Pressure on non-exec's was intense. This was followed by an almost complete management overhaul which brought in Louise Makin from Baxter Pharmaceutical , if I recall correctly. She implemented a healthcare /pharmaceutical strategy and generally she has done that quite well. No complaints so far but I am rather exhausted by the stretching timescales. As for seven times under the current management and its strategy--sorry, enlighten me, I must have missed something!
gregmorg
15/11/2017
13:35
Indeed. We have a marvellous CEO who has built BTG from almost nothing, meanwhile the share price has gone up more tnan seven times. I am sure she will succeed in her FTSE ambitions.
retsig
15/11/2017
09:10
Very welcome comments!
fhmktg
15/11/2017
08:47
Morningstar on 14th published interview with Barnett of Invesco. Apart from an interesting observation on oil he made this comment Pharmaceuticals are another international area Barnett is bullish about. He benefits here from the ability to select non-UK-listed stocks and holds Swiss pharma Roche (RO) as well as many US firms. In the UK, he has big positions in AstraZeneca (AZN) and BTG (BTG). Demographic trends in both developed and emerging markets – ageing populations – are “well established” and “prospects for pipelines are better than we have seen for some time”, he says. In the developing world, “consumers are demanding better standards of healthcare and western drugs and the companies that can benefit from that are the companies that I own”.
ugandalad
14/11/2017
23:40
Last 5 posts from respected long term holders whom I have known for a while probably most sensible posts of the day. My only kick is that btg has had potential for the last 15 years but when are we going to see some heady days? I entered around the 250 mark with a few buys in 300s keen to see the £11 that we have talked about so often or the £21 that we used to talk about
cyman
14/11/2017
12:15
K1P2 I agree this has gone from a snake oil producer with a heady pe of 58 (2013) to a multiproduct company as new treatments have come on stream almost doubling my shares value so its done me well. Think the market is now too pessimistic on its price given the problems with Varithena knocked the PE down when it first came out that there was no insurance claim code. The same issue is knocking the price even though another step forward has been achieved. Waiting a year for the impact on this product is well within my boundaries particularly as the business is profitable,cash generative with cash balances to meet its R&D needs. The loss has been covered by first half profits. I'll await with interest (and hope) for the next 6 months results.
ugandalad
14/11/2017
12:15
Well he may be right but who knows with shares. V is a very good product that works so that what matters in my book. BTG seems to be in a good space and while they have made mistakes thats life but looking forward they seem to be a good bet.
king1pin2
14/11/2017
11:47
Hmm well its a share that i have held for many years so its been one of my very best investments so cant say that i am not happy with the performance apart from a buy at around 7.50.... Still keep the faith .
king1pin2
14/11/2017
11:21
This empire building has got to stop. Expansion only designed to cover up mistakes. Needs a wealthy US predator now.
semper vigilans
14/11/2017
11:18
No, don't short. But this will probably drift down now, as H2 is more quiet and there is no news expected for a while. That said, there could be an acquisition. The credit facility was extended to £300 million. The long term story is still intact and we have a new cfo.
cockneytrader
14/11/2017
11:11
heavens forbid- could that be possible!!
gregmorg
14/11/2017
10:26
Just listining to the webcast , As i thought Inverstment is now minimum and they think that very little money is required to drive sales.
king1pin2
14/11/2017
09:29
ah yes well thats another matter, Volume sales may help with that but its a wait and see as you say.
king1pin2
Chat Pages: Latest  211  210  209  208  207  206  205  204  203  202  201  200  Older
Your Recent History
LSE
BTG
Btg
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190627 02:01:31